HomeCompareMYOV vs VYM

MYOV vs VYM: Dividend Comparison 2026

MYOV yields 7.41% · VYM yields 2.37%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MYOV wins by $4.9K in total portfolio value
10 years
MYOV
MYOV
● Live price
7.41%
Share price
$26.98
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.7K
Annual income
$1,186.18
Full MYOV calculator →
VYM
Vanguard High Dividend Yield ETF
● Live price
2.37%
Share price
$148.10
Annual div
$3.51
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.8K
Annual income
$272.94
Full VYM calculator →

Portfolio growth — MYOV vs VYM

📍 MYOV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMYOVVYM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MYOV + VYM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MYOV pays
VYM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MYOV
Annual income on $10K today (after 15% tax)
$630.10/yr
After 10yr DRIP, annual income (after tax)
$1,008.25/yr
VYM
Annual income on $10K today (after 15% tax)
$201.60/yr
After 10yr DRIP, annual income (after tax)
$232.00/yr
At 15% tax rate, MYOV beats the other by $776.25/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MYOV + VYM for your $10,000?

MYOV: 50%VYM: 50%
100% VYM50/50100% MYOV
Portfolio after 10yr
$30.2K
Annual income
$729.56/yr
Blended yield
2.41%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MYOV right now

MYOV
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-3.0
Piotroski
2/9
VYM
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MYOV buys
0
VYM buys
0
No recent congressional trades found for MYOV or VYM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMYOVVYM
Forward yield7.41%2.37%
Annual dividend / share$2.00$3.51
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$32.7K$27.8K
Annual income after 10y$1,186.18$272.94
Total dividends collected$9.7K$2.6K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: MYOV vs VYM ($10,000, DRIP)

YearMYOV PortfolioMYOV Income/yrVYM PortfolioVYM Income/yrGap
1← crossover$11,441$741.29$11,147$237.17+$294.00MYOV
2$13,035$792.65$12,404$242.33+$631.00MYOV
3$14,791$843.97$13,780$247.16+$1.0KMYOV
4$16,722$895.04$15,285$251.67+$1.4KMYOV
5$18,838$945.65$16,932$255.88+$1.9KMYOV
6$21,152$995.63$18,733$259.81+$2.4KMYOV
7$23,678$1,044.81$20,701$263.46+$3.0KMYOV
8$26,428$1,093.05$22,852$266.86+$3.6KMYOV
9$29,418$1,140.20$25,201$270.01+$4.2KMYOV
10$32,664$1,186.18$27,768$272.94+$4.9KMYOV

MYOV vs VYM: Complete Analysis 2026

MYOVStock

Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.

Full MYOV Calculator →

VYMETF

Seeks to track the performance of the FTSE High Dividend Yield Index, which measures the investment return of common stocks of companies characterized by high dividend yields. Provides a convenient way to track the performance of stocks that are forecasted to have above-average dividend yields. Follows a passively managed, full-replication approach.

Full VYM Calculator →
📬

Get this MYOV vs VYM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MYOV vs SCHDMYOV vs JEPIMYOV vs OMYOV vs KOMYOV vs MAINMYOV vs VIGMYOV vs DGROMYOV vs HDV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.